Cellivery Therapeutics, Inc.

KOSDAQ:A268600 Stock Report

Market Cap: ₩244.9b

Cellivery Therapeutics Valuation

Is A268600 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A268600 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A268600's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A268600's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A268600?

Key metric: As A268600 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A268600. This is calculated by dividing A268600's market cap by their current revenue.
What is A268600's PS Ratio?
PS Ratio10.9x
Sales₩22.57b
Market Cap₩244.94b

Price to Sales Ratio vs Peers

How does A268600's PS Ratio compare to its peers?

The above table shows the PS ratio for A268600 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average19x
A445680 Curiox Biosystems
50.2xn/a₩299.4b
A220100 FutureChemLtd
21.5xn/a₩348.7b
A278650 HLB bioStepLtd
2.9xn/a₩165.9b
A038290 Macrogen
1.2x16.9%₩164.7b
A268600 Cellivery Therapeutics
10.9xn/a₩244.9b

Price-To-Sales vs Peers: A268600 is good value based on its Price-To-Sales Ratio (10.9x) compared to the peer average (16.2x).

Price to Sales Ratio vs Industry

How does A268600's PS Ratio compare vs other companies in the KR Life Sciences Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
A245620 Eone Diagnomics Genome Center
0.8xn/aUS$41.47m
A215380 WOOJUNG BIO
0.5xn/aUS$18.17m
No more companies available in this PS range
A268600 10.9xIndustry Avg. 4.2xNo. of Companies7PS048121620+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A268600 is expensive based on its Price-To-Sales Ratio (10.9x) compared to the KR Life Sciences industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is A268600's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A268600 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A268600's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/20 12:25
End of Day Share Price 2023/03/23 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cellivery Therapeutics, Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution